- Posted By: TreehillPartners
- In: Drug Development
- Posted By: TreehillPartners
- In: Drug Development
- Posted By: TreehillPartners
- In: Drug Development
- Posted By: TreehillPartners
- In: Drug Development, Strategy & Corporate Development
Using a mechanistic pathway or agent to achieve something else than it was designed to do, leaves questions unanswered that will become clear only over
Ali Pashazadeh, Treehill Partners CEO, adds to a discussion on Clinical Trials Arena about how the correct interpretation and use of data is key to
Imperatives around access and accountability. In a roundtable discussion at BioSpace, panelists note how AI can do quite some harm to patients and society in
“My policy as a doctor was always to be very open and transparent – whether that was about morbidity or mortality I was very open.” In
A really interesting article published on Citeline’s TrialScope Intelligence Disclose Perspectives, resulting from an interview with Ali Pashazadeh, Treehill Partners CEO, around his presentation at Citeline’s TrialScope EXTRA conference
Diversity, equity and inclusion (DE&I) continues to be a challenge for drug and medical device developers. While there has been some improvement in clinical trials,
The choices in the drug development model to navigate clinical pathways, and the relationship between drug developers and CROs/ CDMOs can be incredibly complex. Understanding
Louis Garguilo, Chief Editor, Outsourced Pharma, has published the latest part of his interview with Ali Pashazadeh, CEO, Treehill where Ali details why we think
“How do you act as a good corporate citizen and disclose, without jeopardizing the unknown?” As the closing keynote speaker for the first day of Citeline’s
Treehill Partners featured in Biopharma Reporter article by Isabel Cameron, 03 June 2024. As the BIO International 2024 trade show approaches, industry insiders anticipate a
